Literature DB >> 3609117

Non-linear elimination and protein binding of probenecid.

B M Emanuelsson, B Beermann, L K Paalzow.   

Abstract

Six healthy volunteers were given probenecid 0.5, 1 and 2 g p.o. and 0.5 g i.v. The protein binding of probenecid at different concentrations in human plasma was estimated by equilibrium dialysis. The free fraction was found to increase nonlinearly with increasing total probenecid concentration, up to a maximum free fraction of 26%. The plasma concentration-time data after the oral doses were described by a one-compartment open model with first-order absorption and Michaelis-Menten elimination. The mean absorption rate constant 0.0072 min-1 was dose-independent, and the maximal rate of elimination (mean 1429 micrograms/min) did not differ between doses whether calculated from the total or free concentrations. The Michaelis-Menten constant constant decreased significantly from 67.1 to 55.5 micrograms/ml as the dose increased from 1 g to 2 g, while the unbound Michaelis-Menten constant remained unchanged. The elimination of probenecid after the 0.5 g dose was in the linear region of the Michaelis-Menten elimination when calculated from the total and the free concentrations. The volume of distribution increased only slightly from 9.5 to 11.41 as the dose increased from 0.5 to 2 g, but the unbound volume of distribution decreased significantly from 164 to 99 1. Absorption was complete and was independent of the dose administered.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609117     DOI: 10.1007/bf00543976

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Serotonin metabolism in depression: clinical application of the probenecid test.

Authors:  H M van Praag; J Korf
Journal:  Int Pharmacopsychiatry       Date:  1974

Review 2.  Factors affecting drug metabolism.

Authors:  J R Gillette
Journal:  Ann N Y Acad Sci       Date:  1971-07-06       Impact factor: 5.691

3.  Dose-dependent kinetics of probenecid in rhesus monkeys--infusion studies.

Authors:  C W Chiang; L Z Benet
Journal:  Pharmacology       Date:  1984       Impact factor: 2.547

4.  Effect of plasma protein binding on clearance of drugs metabolized by Michaelis--Menten kinetics.

Authors:  K Bachmann; T J Sullivan
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

5.  Extractive alkylation of probenecid in plasma and cerebrospinal fluid and determination by electron-capture gas chromatography.

Authors:  P Hartvig; C Fagerlund; B M Emanuelsson
Journal:  J Chromatogr       Date:  1982-03-12

6.  Pharmacokinetics of salicylate elimination in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1965-07       Impact factor: 3.534

7.  Application of seady-state kinetics to studies of the transfer of 5-hydroxyindoleacetic acid from brain to plasma.

Authors:  N H Neef; T N Tozer; B B Brodie
Journal:  J Pharmacol Exp Ther       Date:  1967-11       Impact factor: 4.030

Review 8.  Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications.

Authors:  J G Wagner
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

9.  Probenecid sensitive pathway of elimination of dopamine and serotonin metabolites in CSF of the rat.

Authors:  J L Elghozi; E Mignot; K H Le Quan-Bui
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

Review 10.  Clinical pharmacokinetics of probenecid.

Authors:  R F Cunningham; Z H Israili; P G Dayton
Journal:  Clin Pharmacokinet       Date:  1981 Mar-Apr       Impact factor: 6.447

View more
  11 in total

1.  Competitive inhibition of renal tubular secretion of gemifloxacin by probenecid.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; George L Drusano; Fritz Sörgel
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

2.  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.

Authors:  Masato Horikawa; Yukio Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

3.  Sulfate homeostasis. IV. Probenecid-induced alterations of inorganic sulfate in rats.

Authors:  I M Darling; M E Morris
Journal:  Pharm Res       Date:  1991-03       Impact factor: 4.200

4.  Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid.

Authors:  Cornelia B Landersdorfer; Carl M J Kirkpatrick; Martina Kinzig; Jürgen B Bulitta; Ulrike Holzgrabe; Ulrich Jaehde; Andreas Reiter; Kurt G Naber; Michael Rodamer; Fritz Sörgel
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

5.  Impact of Mrp2 on the biliary excretion and intestinal absorption of furosemide, probenecid, and methotrexate using Eisai hyperbilirubinemic rats.

Authors:  Cuiping Chen; Dennis Scott; Elizabeth Hanson; Judy Franco; Edwin Berryman; Mario Volberg; Xingrong Liu
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

6.  Pharmacokinetics and tolerability of oseltamivir combined with probenecid.

Authors:  Mark Holodniy; Scott R Penzak; Timothy M Straight; Richard T Davey; Kelvin K Lee; Matthew Bidwell Goetz; Dennis W Raisch; Francesca Cunningham; Emil T Lin; Noemi Olivo; Lawrence R Deyton
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

7.  Clinical Investigation on Endogenous Biomarkers to Predict Strong OAT-Mediated Drug-Drug Interactions.

Authors:  Marie-Emilie Willemin; Thomas K Van Der Made; Ils Pijpers; Lieve Dillen; Annett Kunze; Sophie Jonkers; Kathleen Steemans; An Tuytelaars; Frank Jacobs; Mario Monshouwer; Daniel Scotcher; Amin Rostami-Hodjegan; Aleksandra Galetin; Jan Snoeys
Journal:  Clin Pharmacokinet       Date:  2021-04-10       Impact factor: 5.577

Review 8.  Renal drug transporters and their significance in drug-drug interactions.

Authors:  Jia Yin; Joanne Wang
Journal:  Acta Pharm Sin B       Date:  2016-08-09       Impact factor: 11.413

9.  Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes.

Authors:  Wei Wu; Kevin T Bush; Sanjay K Nigam
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

10.  Prediction of Transporter-Mediated Drug-Drug Interactions for Baricitinib.

Authors:  Maria M Posada; Ellen A Cannady; Christopher D Payne; Xin Zhang; James A Bacon; Y Anne Pak; J William Higgins; Nazila Shahri; Stephen D Hall; Kathleen M Hillgren
Journal:  Clin Transl Sci       Date:  2017-07-27       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.